title: Application status of tamoxifen in endocrine therapy for early breast cancer.
abstract: The aim of the present study was to investigate the application status of tamoxifen as an adjuvant treatment for early-stage breast cancer. Data for patients with early breast cancer were collected from an information management system for breast cancer in a single hospital between 1989 and 2012. The inclusion criteria included no distant metastasis during diagnosis with breast cancer, and a diagnosis of estrogen and/or progesterone receptor-positive breast cancer, or an unclear hormonal receptor status with tamoxifen used as the preferred drug. A total of 2,738 patients were selected, with 99.4% female and 0.6% male patients. Within females, 75.7% were premenopausal when diagnosed with early breast cancer, 24.3% were postmenopausal, and the median age of menopause was 47 years. The percentage of tamoxifen preference in adjuvant therapy was 97.3% prior to 2000, which decreased to 60.4% in 2011. Tamoxifen preference among premenopausal patients reduced from 97.3% prior to 2000 to 89.5% in 2011, while in postmenopausal patients tamoxifen preference declined from 97.4% prior to 2000 to 22.7% in 2011. One-year duration of tamoxifen treatment accounted for 79.4% of cases, while five-year duration accounted for 24.7%. The rate of one-year disease-free survival (DFS) was 98.5% and of five-year DFS was 89.1%. Patients with early breast cancer had a one-year overall survival (OS) rate of 99.2% and a five-year OS rate of 95.6%. The gradually decreased usage and shortened duration of tamixofen treatment, as well as reduced DFS and OS rates were observed in a 'real world' clinical setting. Improved treatment compliance in patients is recommended.
authors.affiliation: Departments of Head and Neck and Mammary Gland Oncology, and Medical Oncology, Cancer Center; State Key Laboratory of Biotherapy, Laboratory of Molecular Diagnosis of Cancer, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China.
authors.forename: Qiancheng
authors.initials: Q
authors.lastname: Hu
authors.affiliation: Departments of Head and Neck and Mammary Gland Oncology, and Medical Oncology, Cancer Center; State Key Laboratory of Biotherapy, Laboratory of Molecular Diagnosis of Cancer, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China.
authors.forename: Ting
authors.initials: T
authors.lastname: Luo
authors.affiliation: Departments of Head and Neck and Mammary Gland Oncology, and Medical Oncology, Cancer Center; State Key Laboratory of Biotherapy, Laboratory of Molecular Diagnosis of Cancer, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China.
authors.forename: Xiaorong
authors.initials: X
authors.lastname: Zhong
authors.affiliation: Departments of Head and Neck and Mammary Gland Oncology, and Medical Oncology, Cancer Center; State Key Laboratory of Biotherapy, Laboratory of Molecular Diagnosis of Cancer, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China.
authors.forename: Ping
authors.initials: P
authors.lastname: He
authors.affiliation: Departments of Head and Neck and Mammary Gland Oncology, and Medical Oncology, Cancer Center; State Key Laboratory of Biotherapy, Laboratory of Molecular Diagnosis of Cancer, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China.
authors.forename: Tinglun
authors.initials: T
authors.lastname: Tian
authors.affiliation: Departments of Head and Neck and Mammary Gland Oncology, and Medical Oncology, Cancer Center; State Key Laboratory of Biotherapy, Laboratory of Molecular Diagnosis of Cancer, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China.
authors.forename: Hong
authors.initials: H
authors.lastname: Zheng
keywords: application status; early-stage breast cancer; hormonal receptor-positive; tamoxifen